Tracy T S, Hall S D
Department of Medicine, Indiana University School of Medicine, Wishard Memorial Hospital, Indianapolis 46202-2879.
Drug Metab Dispos. 1992 Mar-Apr;20(2):322-7.
Ibuprofen [(racemic)2-(4-isobutylphenyl)propionic acid] has been proposed but not directly demonstrated to undergo unidirectional inversion from the (R)- to the (S)-configuration via a coenzyme A (CoA) thioester intermediate. Chemically synthesized (R)- and (S)-ibuprofenyl-CoA, and rat and human liver homogenates were used to investigate the relative rates of ibuprofenyl-CoA epimerization and hydrolysis. Rat whole liver homogenate completely epimerized (R)- or (S)-ibuprofenyl-CoA, whereas hydrolysis of this intermediate occurred at a much slower rate. Rat liver mitochondria was the most efficient at both epimerizing and hydrolyzing ibuprofenyl-CoA, whereas rat liver microsomes hydrolyzed ibuprofenyl-CoA at a rate similar to whole liver homogenate but had very little epimerization activity. Rat liver cytosol was the poorest at hydrolyzing ibuprofenyl-CoA but had substantial epimerization capability. Whole liver homogenate from human tissue was less efficient at epimerizing but as efficient at hydrolyzing ibuprofenyl-CoA as rat whole liver homogenate. No stereoselectivity of either epimerization or hydrolysis was noted for any of the enzyme preparations studied. This study demonstrates that the inversion of (R)-ibuprofen occurs, at least in part, via the epimerization of the metabolic intermediate, ibuprofenyl-CoA, in both rat and human liver tissues.
布洛芬[(消旋)2-(4-异丁基苯基)丙酸]已被提出,但尚未直接证明其通过辅酶A(CoA)硫酯中间体从(R)构型单向转化为(S)构型。使用化学合成的(R)-和(S)-布洛芬辅酶A以及大鼠和人肝脏匀浆来研究布洛芬辅酶A差向异构化和水解的相对速率。大鼠全肝匀浆可使(R)-或(S)-布洛芬辅酶A完全差向异构化,而该中间体的水解速率要慢得多。大鼠肝线粒体在使布洛芬辅酶A差向异构化和水解方面效率最高,而大鼠肝微粒体水解布洛芬辅酶A的速率与全肝匀浆相似,但差向异构化活性很低。大鼠肝细胞溶胶水解布洛芬辅酶A的能力最差,但具有相当大的差向异构化能力。人组织的全肝匀浆在使布洛芬辅酶A差向异构化方面效率较低,但在水解布洛芬辅酶A方面与大鼠全肝匀浆效率相同。在所研究的任何酶制剂中,均未观察到差向异构化或水解的立体选择性。这项研究表明,(R)-布洛芬的转化至少部分是通过代谢中间体布洛芬辅酶A在大鼠和人肝脏组织中的差向异构化发生的。